Honasa Consumer recommends ₹3 final dividend, sets Sep 28 AGM date

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Honasa Consumer recommends a final dividend of ₹3 per equity share for FY26
  • The 10th AGM is scheduled for September 28, 2026, to approve the payout
  • Record date for dividend eligibility is set as August 28, 2026
  • Shareholders must submit TDS documents by September 10, 2026, via KFin Technologies
powered bylight_fuzz_icon
48863856

*this image is generated using AI for illustrative purposes only.

Honasa Consumer has scheduled its 10th Annual General Meeting (AGM) for September 28, 2026. The Board of Directors recommended a final dividend of ₹3 per equity share for FY26, subject to shareholder approval at the meeting.

The dividend represents a 30% payout on the face value of ₹10 per share. Shareholders whose names appear in the Register of Members or beneficial owner lists as of the close of business on August 28, 2026, will be eligible for the payment.

Dividend and Record Date Details

Parameter Detail
Final Dividend ₹3 per equity share
Face Value ₹10 per share
Payout Ratio 30%
Record Date August 28, 2026
AGM Date September 28, 2026

The company will deduct tax at source (TDS) from dividend payments as per the Income Tax Act, 2025. The applicable tax rate depends on the residential status of members and documents submitted. Shareholders must update bank account details with their Depository Participants to ensure direct credit, as physical dividend warrants have been discontinued since November 18, 2025.

Tax Documentation Deadline

To claim nil or lower TDS rates, members must submit requisite documents via the Registrar and Share Transfer Agent, KFin Technologies Limited. The last date for submission is September 10, 2026. Required forms include self-declarations for resident and non-resident shareholders, available on the company’s website.

Meeting Logistics and Voting

Members can attend the AGM via video conference or other audio-visual means in accordance with Ministry of Corporate Affairs circulars. Remote electronic voting facilities are available. Notices and the Annual Report for FY26 will be sent electronically to registered email addresses.

Physical copies can be requested by writing to compliance@honasa.in with DP ID and Client ID details. For e-voting assistance, members may contact CDSL at helpdesk.evoting@cdslindia.com or call 1800 21 09911.

Historical Stock Returns for Mamaearth

1 Day5 Days1 Month6 Months1 Year5 Years
+0.01%+0.53%-1.71%+63.78%+57.15%+40.51%

How does Honasa Consumer's 30% payout ratio compare to its historical dividend trends and competitors in the D2C beauty sector?

What impact might the discontinuation of physical dividend warrants have on retail investor engagement and administrative costs for the company?

Will the proposed ₹3 per share dividend be sufficient to attract institutional investors given the current valuation of Honasa Consumer?

Honasa Consumer calls off Fluence Pharma deal over unmet conditions

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Honasa Consumer terminated its proposed acquisition of a 58% stake in Fluence Pharma
  • The deal was called off due to non-fulfilment of closing conditions in the Share Purchase Agreement
  • The announcement was made on August 25, 2026, following an initial proposal in June 2026
  • Honasa remains committed to its nutraceutical strategy and will evaluate further opportunities
powered bylight_fuzz_icon
49218837

*this image is generated using AI for illustrative purposes only.

Honasa Consumer Limited terminated its proposed acquisition of a 58% equity stake in Fluence Pharma Private Limited. The cancellation was announced on August 25, 2026, citing the non-fulfilment of closing conditions specified in the Share Purchase Agreement.

The disclosure follows an earlier notification dated June 23, 2026, which had outlined the proposed acquisition subject to the completion of specific conditions precedent.

Regulatory Disclosure

The update was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both the National Stock Exchange of India Limited and BSE Limited regarding the termination of the transaction.

Strategic Outlook

Honasa stated it remains committed to its nutraceutical strategy. The company indicated it will continue to evaluate organic and inorganic opportunities to build a consumer-focused business in this category.

Transaction Details

Parameter Details
Target Company Fluence Pharma Private Limited
Proposed Stake 58% equity
Status Called off
Reason Non-fulfilment of closing conditions
Announcement Date August 25, 2026

The disclosure was signed by Gaurav Pandit, Company Secretary and Compliance Officer, on behalf of Honasa Consumer Limited.

Historical Stock Returns for Mamaearth

1 Day5 Days1 Month6 Months1 Year5 Years
+0.01%+0.53%-1.71%+63.78%+57.15%+40.51%
Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

How might the termination of the Fluence Pharma acquisition impact Honasa Consumer's near-term revenue growth projections and market valuation?

Will Honasa Consumer prioritize organic R&D expansion or seek alternative inorganic targets to accelerate its nutraceutical portfolio?

What specific closing conditions were not met, and does this indicate broader regulatory or operational hurdles in the Indian nutraceutical M&A landscape?

More News on Mamaearth

1 Year Returns:+57.15%